JP2012509279A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012509279A5 JP2012509279A5 JP2011536613A JP2011536613A JP2012509279A5 JP 2012509279 A5 JP2012509279 A5 JP 2012509279A5 JP 2011536613 A JP2011536613 A JP 2011536613A JP 2011536613 A JP2011536613 A JP 2011536613A JP 2012509279 A5 JP2012509279 A5 JP 2012509279A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- compound
- composition
- disorder
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 208000035475 disorder Diseases 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 7
- 230000002062 proliferating effect Effects 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000003981 vehicle Substances 0.000 claims description 3
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 238000002441 X-ray diffraction Methods 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 230000001028 anti-proliverative effect Effects 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 239000013078 crystal Substances 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 208000037819 metastatic cancer Diseases 0.000 claims description 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 230000000973 chemotherapeutic effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 7
- 229940125904 compound 1 Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11603308P | 2008-11-19 | 2008-11-19 | |
| US61/116,033 | 2008-11-19 | ||
| PCT/US2009/064909 WO2010059668A1 (en) | 2008-11-19 | 2009-11-18 | A triazolothiadiazole inhibitor of c-met protein kinase |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012509279A JP2012509279A (ja) | 2012-04-19 |
| JP2012509279A5 true JP2012509279A5 (enExample) | 2012-12-27 |
| JP5596047B2 JP5596047B2 (ja) | 2014-09-24 |
Family
ID=42027848
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011536613A Expired - Fee Related JP5596047B2 (ja) | 2008-11-19 | 2009-11-18 | ｃ−Ｍｅｔタンパク質キナーゼのトリアゾロチアジアゾール阻害剤 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US8217056B2 (enExample) |
| EP (1) | EP2365977B1 (enExample) |
| JP (1) | JP5596047B2 (enExample) |
| KR (1) | KR20110094285A (enExample) |
| CN (1) | CN102216309B (enExample) |
| AR (1) | AR074379A1 (enExample) |
| AU (1) | AU2009316756B2 (enExample) |
| BR (1) | BRPI0921509A2 (enExample) |
| CA (1) | CA2743000A1 (enExample) |
| CL (1) | CL2011001152A1 (enExample) |
| ES (1) | ES2393693T3 (enExample) |
| IL (1) | IL212906A0 (enExample) |
| MX (1) | MX2011005250A (enExample) |
| NZ (1) | NZ592825A (enExample) |
| RU (1) | RU2011124894A (enExample) |
| TW (1) | TW201024309A (enExample) |
| WO (1) | WO2010059668A1 (enExample) |
| ZA (1) | ZA201103170B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2166010A1 (en) * | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
| EP2166008A1 (en) * | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
| JP5596047B2 (ja) * | 2008-11-19 | 2014-09-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | ｃ−Ｍｅｔタンパク質キナーゼのトリアゾロチアジアゾール阻害剤 |
| SI2435443T1 (sl) * | 2009-05-28 | 2013-12-31 | Vertex Pharmaceuticals Incorporated | Aminopirazol triazolotiadiazolni inhibitorji c-met protein kinaze |
| CA2762186A1 (en) * | 2009-05-28 | 2010-12-02 | Vertex Pharmaceuticals Incorporated | Substituted pyrazole inhibitors of c-met protein kinase |
| WO2010138673A1 (en) * | 2009-05-28 | 2010-12-02 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-met protein kinase |
| CN109283279B (zh) * | 2017-07-21 | 2019-11-01 | 南京正大天晴制药有限公司 | 通过高效液相色谱法分离测定雷替曲塞及其对映异构体的方法 |
| CN109897054B (zh) * | 2017-12-08 | 2021-12-10 | 中国药科大学 | 三唑并噻二唑类c-Met激酶抑制剂的制备方法及其用途 |
| AU2020242287A1 (en) | 2019-03-21 | 2021-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A Dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20080080584A (ko) * | 2005-11-30 | 2008-09-04 | 버텍스 파마슈티칼스 인코포레이티드 | ｃ-Ｍｅｔ의 억제제 및 이의 용도 |
| JP2009538899A (ja) * | 2006-05-30 | 2009-11-12 | ファイザー・プロダクツ・インク | トリアゾロピリダジン誘導体 |
| CN101678014B (zh) * | 2007-05-21 | 2012-12-12 | Sgx药品公司 | 杂环激酶调节剂 |
| JP5596047B2 (ja) * | 2008-11-19 | 2014-09-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | ｃ−Ｍｅｔタンパク質キナーゼのトリアゾロチアジアゾール阻害剤 |
-
2009
- 2009-11-18 JP JP2011536613A patent/JP5596047B2/ja not_active Expired - Fee Related
- 2009-11-18 BR BRPI0921509A patent/BRPI0921509A2/pt not_active Application Discontinuation
- 2009-11-18 US US12/620,845 patent/US8217056B2/en not_active Expired - Fee Related
- 2009-11-18 WO PCT/US2009/064909 patent/WO2010059668A1/en not_active Ceased
- 2009-11-18 RU RU2011124894/04A patent/RU2011124894A/ru unknown
- 2009-11-18 MX MX2011005250A patent/MX2011005250A/es active IP Right Grant
- 2009-11-18 ES ES09756109T patent/ES2393693T3/es active Active
- 2009-11-18 CN CN200980146238.2A patent/CN102216309B/zh not_active Expired - Fee Related
- 2009-11-18 AU AU2009316756A patent/AU2009316756B2/en not_active Ceased
- 2009-11-18 KR KR1020117011277A patent/KR20110094285A/ko not_active Withdrawn
- 2009-11-18 CA CA2743000A patent/CA2743000A1/en not_active Abandoned
- 2009-11-18 EP EP09756109A patent/EP2365977B1/en active Active
- 2009-11-18 NZ NZ592825A patent/NZ592825A/xx not_active IP Right Cessation
- 2009-11-19 TW TW098139384A patent/TW201024309A/zh unknown
- 2009-11-19 AR ARP090104468A patent/AR074379A1/es unknown
-
2011
- 2011-04-29 ZA ZA2011/03170A patent/ZA201103170B/en unknown
- 2011-05-03 US US13/099,643 patent/US8343998B2/en not_active Expired - Fee Related
- 2011-05-16 IL IL212906A patent/IL212906A0/en unknown
- 2011-05-18 CL CL2011001152A patent/CL2011001152A1/es unknown
- 2011-08-10 US US13/206,954 patent/US20110301195A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012509279A5 (enExample) | ||
| JP2010528026A5 (enExample) | ||
| CA2606719A1 (en) | Amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and process for producing the same | |
| JP2020500862A5 (enExample) | ||
| RU2011124894A (ru) | Триазолотиадиазоловый ингибитор протеинкиназы с-мет | |
| JP2022121594A5 (enExample) | ||
| JP2009513662A5 (enExample) | ||
| JP2009502743A5 (enExample) | ||
| JP2016006096A5 (enExample) | ||
| JP2012506381A5 (enExample) | ||
| JP2008521928A5 (enExample) | ||
| JP2014502641A5 (enExample) | ||
| JP2019501204A5 (enExample) | ||
| JP2013522232A5 (enExample) | ||
| JP2013519645A5 (enExample) | ||
| JP2010540555A5 (enExample) | ||
| JP2014515351A5 (enExample) | ||
| JP2013509411A5 (enExample) | ||
| JP2015096544A5 (enExample) | ||
| JP2018538273A5 (enExample) | ||
| JP2013522326A5 (enExample) | ||
| JP2015522589A5 (enExample) | ||
| JP2020531463A5 (enExample) | ||
| JP2015193630A5 (enExample) | ||
| JP2016522254A5 (enExample) |